Laboratory experiments at Princeton University and TGen, testing a ketogenic diet, lead to nationwide clinical trial
Category Archives: AZBio News
Are You Ready for the Rise in Virtual Care (Guest Post by LIFE365)
The rise in virtual care has opened the door for healthcare delivery transformation. This rise can be linked back to the pandemic, and new reimbursement opportunities for remote care services, which have fueled the adoption of digital health technologies, including remote patient monitoring.Continue reading
Arizona Commerce Authority offering a registration reimbursement grant for TechConnect Conference 2022
TechConnect is the premier SBIR conference where companies across the country gather to hear from experts and connect directly with SBIR program managers. Many companies credit the experience and knowledge they gained from attending with helping them submit a successful SBIR application.
The Arizona Commerce Authority understands that the cost of travel and accommodations may not be feasible for everyone, so they are offering a registration reimbursement
HTG Molecular Diagnostics Announces $7.5 Million Private Placement
TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes.
TGen, HonorHealth and Irish biomedical firm initiate promising ‘Nieto’ clinical trial against pancreatic cancer
Named for a respected Arizona scientist, this trial uses a combination of drugs against advanced cancer in patients where other treatments have failed
Nearly 100 Organizations and Experts Urge HHS Secretary Xavier Becerra to Reject Xtandi March-In Petition
WASHINGTON, D.C. (March 17) — In a letter transmitted today, the Bayh-Dole Coalition and nearly 100 prominent academic and private sector innovation experts and organizations, public policy associations, and legal scholars urged U.S. Department of Health and Human Services Secretary Xavier Becerra to reject the latest march-in petition on prostate cancer drug Xtandi.Continue reading
BioTech Company PathogenDx Strengthens Executive Team; Announces Several New Key Leadership Appointments
PathogenDx Appoints Foremost Industry and Topic Experts as Its Advanced Microarray Testing Platform Sets New Standards in DNA-Based TestingContinue reading
Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas
Study offers therapeutic expansion phase for patients with a positive pharmacokinetic response to investigational drug
C-Path and Tufts Medical Center Collaborate on EHR Data Transfer
The endeavor represents a major milestone for C-PathContinue reading
UArizona engineer leads $1M project to fight vision loss
Biomedical engineering and optical sciences professor DK Kang is developing a way to diagnose and treat corneal ulcers that’s eight times cheaper and 20 times faster than today’s gold standard.Continue reading